Fanconi anemia (FA) is a rare autosomal recessive disease characterized by congenital abnormalities, cancer predisposition and progressive BM failure. FA patients present spontaneous and induced chromosome breakage. Hematopoietic SCT (HSCT) represents the unique therapeutic option to restore normal hematopoiesis when marrow failure or clonal hematopoietic abnormality occurs. Conventional myeloablative conditioning regimen, especially including a high dose of irradiation, appeared strongly toxic for FA patients. Then, reduced-intensity conditioning regimens were developed successfully for those patients. However, TRM still remained higher than for other HSCT indications. The development of fludarabine containing a non-myeloablative conditioning regimen appears to be a major progress. Long-term follow-up is absolutely necessary.
Introduction
Fanconi anemia (FA) is an autosomal recessive disorder characterized by congenital abnormalities, progressive BM failure and cancer predisposition. Even though this disorder is rare with an incidence of 1 per 100 000 live births, FA represents the most common inherited BM failure syndrome. 1 It is phenotypically and genotypically very heterogeneous. Phenotypically, patients could present patchy brown melanin-like pigmentation of the skin, shortness of stature, skeletal anomalies (especially radial abnormalities), microcephaly, abnormalities of the ears, and renal and cardiac anomalies. Patient cells exhibit a huge sensitivity to DNA cross-linking agents and oxidative agents such as alkylating agents or ionizing radiation. 2 To date, at least 13 genes have been identified in this disease. These genes interact with the FA/BRCA pathway that is a crucial pathway for DNA repair. 3, 4 This genetic pattern is responsible in FA patients for both BM failure syndrome and high incidence of squamous cell carcinoma. 5 On the basis of clinical data from both the International Fanconi Anemia Registry (IFAR) and the German Fanconi Anemia Registry (GEFA), it appears that 50-90% of FA patients have a risk of BM failure by age 40 years. [6] [7] [8] In GEFA, the ratio of observed to expected cancers was 44 for all cancers, from 26 for all solid tumors (up to 6281 for esophageal squamous cell carcinoma) to 868 for AML.
Fanconi anemia diagnosis could be performed by different in vitro biological tests as a demonstration of the presence of increased chromosomal breakage in lymphocytes cultured in the presence of DNA cross-linking agents such as mitomycine C, demonstration of G2/M arrest after exposure to clastogenic agents by flow cytometry or demonstration of FANCD2 ubiquitination (except for patients with mutation in FA genes downstream of FANCD2). 4 
Current results
The natural history of FA ends in lethal BM failure. Hematopoietic SCT (HSCT) represents the only therapeutic option to restore normal hematopoiesis when marrow failure or clonal hematopoietic abnormality occurs.
As expected, HSCT is unable to modify non-hematopoietic defects and abnormalities occurring in FA patients. The very high sensitivity to oxidative agents and DNA cross-linking agents confers very peculiar tissue fragility. Then, when these patients undergo HSCT, they experience unusual and severe toxicities including cardiac myopathy, gastrointestinal hemorrhage, hemorrhagic cystitis and radiation skin burns. These toxicities mean that the classical myeloablative conditioning regimen must be avoided, as demonstrated by Gluckman et al.,
9-11 on account of the toxicity induced by high-dose CY or highdose irradiation. In the same way, the occurrence of either severe acute or chronic GVHD leads to greater tissue damage than that occurs in non-FA patients. Thus, for decades, the development of adapted low-intensity conditioning regimen and selection of graft associated to the lowest GVHD risk were the main goals of physicians.
In 1998, the Saint-Louis group described the long-term follow-up of 50 FA patients transplanted from a sibling donor after low-dose CY (20 mg/kg total dose) and thoraco-abdominal irradiation (500 cGy) as conditioning regimen. 12 With this treatment, 74 and 58% of patients survived at 54 and 100 months, respectively, after transplantation. The occurrence of chronic GVHD and the use of more than 20 pre-transplant transfusions appeared to have significant adverse impact on survival by multivariate analysis. During the same period, the Seattle group reported similar results using reducedintensity conditioning regimen without any irradiation. In addition, in this study the incidence of both acute and chronic GVHD appeared to be lower than in the French study. 13 Then, a conditioning regimen avoiding any radiation and including anti-thymoglobulins was developed. However, such a conditioning regimen could not prevent any solid tumor occurrence because of higher risk of squamous cell carcinoma in all FA patients, including non-transplanted ones. Finally, as summarized by Gluckman and Wagner 14 in a recent review, the best conditioning regimen must prevent rejection in population of patients who have received multiple transfusions, must limit early and late toxicities and must minimize the risk of GVHD. In addition, it seemed very important to plan transplantation before the appearance of abnormal clonality by at least a yearly BM examination. Because of the strong side effects induced in vitro by alkylating agents such as CY on FA cell lines, it appeared interesting to develop a conditioning regimen without this type of chemotherapy. In 1997, Kapelushnik et al. 15 from Israel published the first case report using a fludarabine-based conditioning regimen for an FA child in leukemic transformation. They were followed by many groups all over the world, and currently fludarabine-based conditioning regimens are considered as the gold standard for FA patient transplantation. In 2007, Wagner et al. 16 reported the long-term results in 98 FA patients who underwent unrelated BMT from 1990 to 2003 in centers collaborating with the National Marrow Donor Program. They showed higher probabilities of neutrophil and platelet recovery after fludarabine-containing regimens than non-fludarabine containing regimens did. Similarly, TRM and 3-year adjusted overall survival rates appeared better after fludarabine based conditioning regimens than non-fludarabine based regimens (65 vs 24% and 13 vs 52%, respectively). The other significant poor prognostic factors for mortality in this paper were patient age more than 10 years, CMV seropositivity and more than 20 blood product transfusions before transplantation. The authors emphasized practice changes including fludarabine-containing conditioning regimens to obtain strong T-cell depletion and early transplantation in FA patients exhibiting marrow failure. Recently, Yabe et al. 17 performed in vitro experiments that demonstrated the rationale for using fludarabine in these patients. The difference in breakage frequencies between FA and non-FA patient lymphocytes for cultures treated with fludarabine was not statistically significant. Nevertheless, some teams still remained satisfied by the results obtained with the 'old' conditioning regimen based on CY, thoraco-abdominal radiation and antithymocyte globulin. For example, Cincinnati Children's Hospital Medical Center reported 89% of actuarial survival at 10 years among 35 FA patients who received matched sibling donor HSCT in a single center experience. 18 In the same way, the experience reported in Saudi Arabia appeared interesting after conditioning containing CY, antithymocyte globulin and TBI at 450 cGy for FA patients with myelodysplasia. 19 Finally, drugs associated with fludarabine and addition of ionizing irradiations still remain to be discussed, according to donor type (either related or unrelated) and/or according to marrow clonal abnormality occurrence before transplantation. In 2006, Bitan et al. 20 reported excellent results regarding seven patients who underwent HSCT from either matched sibling or matched unrelated donor after fludarabine-based reduced-intensity conditioning regimen without radiation. In this short cohort, all seven patients were alive with 100% performance status. At the time of publication, no patient had developed secondary malignancy. Other groups still use the fludarabine-based conditioning regimen containing low-dose radiation (200-400 cGy) when patients are transplanted from unrelated donors. 21 For patients without matched sibling or unrelated donor, unrelated partially matched cord blood might represent an acceptable alternative. In this setting, Gluckman et al. 22 recently reported the Eurocord results regarding 97 patients. Overall survival was 40 ± 5% with better results for those who received fludarabine-based conditioning regimen, high cell dose and who were CMV seronegative.
Conclusion
Hematopoietic stem cell transplantation is the only curative therapy for marrow failure experienced by FA patients. The best stem cell source for these patients is a matched sibling donor. However, current results for patients who received HSCT from alternative donors, either unrelated fully matched volunteer donors or unrelated partially matched cord blood, suggest that these alternatives are acceptable. The most important progress during the last decade was the introduction of fludarabine in conditioning regimens. Long-term monitoring is absolutely required in FA patients because of their particular sensitivity to toxic agents and increased risk of developing malignancies.
